Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Rang in Aktien #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Aktienkurs
$0.15
Marktkapitalisierung
$4.96M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel Intellipharmaceutics International Inc. (IPCIF)

Kategorie

Gewinn für Intellipharmaceutics International Inc. (IPCIF)
Gewinn im Aug 2023 TTM: $-3.17M
Laut den aktuellen Finanzberichten von Intellipharmaceutics International Inc. betragen die aktuellen Gewinne des Unternehmens $-3.17M. Im Jahr 2021 erzielte das Unternehmen einen Gewinn von $-2.89M, eine Steigerung gegenüber dem Gewinn im Jahr 2020, der $-5.26M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Intellipharmaceutics International Inc. von 1999 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-3.17M 9.75%
2022 $-2.89M 0.00%
2021 $-2.89M -45.11%
2020 $-5.26M 56.62%
2019 $-3.36M -75.57%
2018 $-13.75M 55.21%
2017 $-8.86M -12.68%
2016 $-10.14M 36.40%
2015 $-7.44M 92.83%
2014 $-3.86M -66.45%
2013 $-11.50M 135.54%
2012 $-4.88M 95.22%
2011 $-2.50M -56.34%
2010 $-5.73M -55.76%
2008 $-12.94M -56.95%
2007 $-30.07M -49.08%
2006 $-59.05M -25.61%
2005 $-79.37M 13.77%
2004 $-69.77M 173.92%
2003 $-25.47M 104.32%
2002 $-12.47M 36.27%
2001 $-9.15M 41.00%
2000 $-6.49M 0.00%
1999 0.00 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
$20.46B -645,746.69%
DK
$4.64B -146,643.73%
US
$5.23B -165,185.78%
US
$2.14B -67,567.64%
BE
$1.45B -45,897.45%
NL